Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Diseases, Genetic Clear all
Completed No phase listed Observational

An Exploratory Genetic Study in Participants With Psoriasis

NCT02155192
View directory record Official record
Conditions
Psoriasis
Interventions
No Intervention
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
12
States / cities
Bakersfield, California • Los Angeles, California • Ocala, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Jun 26, 2026, 5:24 PM EDT
Enrolling by invitation Phase 3 Interventional

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

NCT06431893
View directory record Official record
Conditions
Homocystinuria
Interventions
Pegtibatinase
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Phoenix, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

NCT02475447
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • North Miami Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

Eucrisa for Atopic Dermatitis

NCT03250663
View directory record Official record
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
Online Treatment response, EUCRISA
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Jun 26, 2026, 5:24 PM EDT
Recruiting No phase listed Observational

Longitudinal Study of Neurodegenerative Disorders

NCT03333200
View directory record Official record
Conditions
MLD, Krabbe Disease, ALD, MPS I, MPS II, MPS III, Vanishing White Matter Disease, GM3 Gangliosidosis, PKAN, Tay-Sachs Disease, NP Deficiency, Osteopetrosis, Alpha-Mannosidosis, Sandhoff Disease, Niemann-Pick Diseases, MPS IV, Gaucher Disease, GAN, GM1 Gangliosidoses, Morquio Disease, S-Adenosylhomocysteine Hydrolase Deficiency, Batten Disease, Pelizaeus-Merzbacher Disease, Leukodystrophy, Lysosomal Storage Diseases, Purine Nucleoside Phosphorylase Deficiency, Multiple Sulfatase Deficiency Disease
Interventions
Palliative Care, Hematopoetic Stem Cell Transplantation
Other · Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Not applicable Interventional Results available

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

NCT01626092
View directory record Official record
Conditions
Lysosomal Storage Disease, Peroxisomal Disorder
Interventions
Campath-1H, Clofarabine, Melphalan, Total Body Irradiation with Marrow Boosting, Hematopoietic stem cell transplantation, Cyclosporine A, Mycophenolate mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jun 26, 2026, 5:24 PM EDT
Enrolling by invitation Not applicable Interventional

Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes

NCT06914726
View directory record Official record
Conditions
Hereditary Breast/Ovarian Cancer (brca1, brca2), Lynch Syndrome, Genetic Variation, HBOC Syndrome, Hereditary Cancer Syndromes
Interventions
Patient Centered Clinical Decision Support (PC-CDS)
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
2,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jun 26, 2026, 5:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

NCT00040352
View directory record Official record
Conditions
Melanoma, Dysplastic Nevus Syndrome
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Weeks to 99 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

NCT00630747
View directory record Official record
Conditions
Hunter Syndrome, Mucopolysaccharidosis II (MPS II)
Interventions
Idursulfase
Biological
Lead sponsor
Shire
Industry
Eligibility
5 Years and older · Male only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
16
States / cities
Phoenix, Arizona • Oakland, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Dosing Study of Replagal in Patients With Fabry Disease

NCT00068107
View directory record Official record
Conditions
Fabry Disease
Interventions
Replagal
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

NCT03338816
View directory record Official record
Conditions
Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
Interventions
Givosiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Jun 26, 2026, 5:24 PM EDT
Completed No phase listed Observational

Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

NCT03688204
View directory record Official record
Conditions
Breast Cancer Risk
Interventions
Not listed
Lead sponsor
Ambry Genetics
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Burbank, California • Orange, California • Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

NCT05375955
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Jun 26, 2026, 5:24 PM EDT
Recruiting Not applicable Interventional

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

NCT04751435
View directory record Official record
Conditions
Educational Materials for Genetic Testing, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions
Cognitive interview, LCAM intervention, Standard of care
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Brooklyn, New York • Jamaica, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Korean Translation and Validation of the K-HEPI in NYC

NCT05544578
View directory record Official record
Conditions
Disaster, Vulnerable Populations
Interventions
Nurses Taking On Readiness Measures (N- TORM)
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment for Cellulite Appearance

NCT05358847
View directory record Official record
Conditions
Cellulite
Interventions
Sofwave
Device
Lead sponsor
Sofwave Medical LTD
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Sacramento, California • New York, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jun 26, 2026, 5:24 PM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

NCT05399368
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 26, 2026, 5:24 PM EDT
Terminated Phase 2 Interventional Results available

Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

NCT05312697
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Setrusumab
Biological
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
19 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jun 26, 2026, 5:24 PM EDT
Withdrawn Phase 1 Interventional

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

NCT05238324
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
Genetic HMI-203
Biological
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
5
States / cities
Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Jun 26, 2026, 5:24 PM EDT
Terminated Phase 2 Interventional Results available

Panhematin for Prevention of Acute Attacks of Porphyria

NCT02922413
View directory record Official record
Conditions
Acute Intermittent Porphyria, Hereditary Coproporphyria, Variegate Porphyria
Interventions
Hemin for injection, Placebo
Biological · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

NCT01737710
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jun 26, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jun 26, 2026, 5:24 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

NCT06055361
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BxC-I17e (primed iMSC derived Extracellular vesicles(EV)), Placebo
Drug
Lead sponsor
Brexogen Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
North Little Rock, Arkansas • Camp Hill, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 26, 2026, 5:24 PM EDT